BACKGROUND: The extent which universally common or population-specific alleles can explain between-population variations in phenotypes is unknown. The heritable coronary heart disease risk factor lipoprotein(a) (Lp(a)) level provides a useful case study of between-population variation, as the aetiology of twofold higher Lp(a) levels in African populations compared with non-African populations is unknown. OBJECTIVE: To evaluate the association between LPA sequence variations and Lp(a) in European Americans and African Americans and to determine the extent to which LPA sequence variations can account for between-population variations in Lp(a). METHODS: Serum Lp(a) and isoform measurements were examined in 534 European Americans and 249 African Americans from the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease Study. In addition, 12 LPA variants were genotyped, including 8 previously reported LPA variants with a frequency of >2% in European Americans or African Americans, and four new variants. RESULTS: Isoform-adjusted Lp(a) level was 2.23-fold higher among African Americans. Three single-nucleotide polymorphisms (SNPs) were independently associated with Lp(a) level (p<0.02 in both populations). The Lp(a)-increasing SNP (G-21A, which increases promoter activity) was more common in African Americans, whereas the Lp(a)-lowering SNPs (T3888P and G+1/inKIV-8A, which inhibit Lp(a) assembly) were more common in European Americans, but all had a frequency of <20% in one or both populations. Together, they reduced the isoform-adjusted African American Lp(a) increase from 2.23 to 1.37-fold(a 60% reduction) and the between-population Lp(a) variance from 5.5% to 0.5%. CONCLUSIONS: Multiple low-prevalence alleles in LPA can account for the large between-population difference in serum Lp(a) levels between European Americans and African Americans.
BACKGROUND: The extent which universally common or population-specific alleles can explain between-population variations in phenotypes is unknown. The heritable coronary heart disease risk factor lipoprotein(a) (Lp(a)) level provides a useful case study of between-population variation, as the aetiology of twofold higher Lp(a) levels in African populations compared with non-African populations is unknown. OBJECTIVE: To evaluate the association between LPA sequence variations and Lp(a) in European Americans and African Americans and to determine the extent to which LPA sequence variations can account for between-population variations in Lp(a). METHODS: Serum Lp(a) and isoform measurements were examined in 534 European Americans and 249 African Americans from the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease Study. In addition, 12 LPA variants were genotyped, including 8 previously reported LPA variants with a frequency of >2% in European Americans or African Americans, and four new variants. RESULTS: Isoform-adjusted Lp(a) level was 2.23-fold higher among African Americans. Three single-nucleotide polymorphisms (SNPs) were independently associated with Lp(a) level (p<0.02 in both populations). The Lp(a)-increasing SNP (G-21A, which increases promoter activity) was more common in African Americans, whereas the Lp(a)-lowering SNPs (T3888P and G+1/inKIV-8A, which inhibit Lp(a) assembly) were more common in European Americans, but all had a frequency of <20% in one or both populations. Together, they reduced the isoform-adjusted African American Lp(a) increase from 2.23 to 1.37-fold(a 60% reduction) and the between-population Lp(a) variance from 5.5% to 0.5%. CONCLUSIONS: Multiple low-prevalence alleles in LPA can account for the large between-population difference in serum Lp(a) levels between European Americans and African Americans.
Authors: Noah A Rosenberg; Jonathan K Pritchard; James L Weber; Howard M Cann; Kenneth K Kidd; Lev A Zhivotovsky; Marcus W Feldman Journal: Science Date: 2002-12-20 Impact factor: 47.728
Authors: Brad C Astor; Joseph A Eustace; Michael J Klag; Neil R Powe; J Craig Longenecker; Nancy E Fink; Santica M Marcovina; Josef Coresh Journal: Kidney Int Date: 2002-03 Impact factor: 10.612
Authors: Sotirios Tsimikas; Emmanouil S Brilakis; Elizabeth R Miller; Joseph P McConnell; Ryan J Lennon; Kenneth S Kornman; Joseph L Witztum; Peter B Berger Journal: N Engl J Med Date: 2005-07-07 Impact factor: 91.245
Authors: Benjamin M Morgan; Aimee N Brown; Nikita Deo; Tom W R Harrop; George Taiaroa; Peter D Mace; Sigurd M Wilbanks; Tony R Merriman; Michael J A Williams; Sally P A McCormick Journal: J Lipid Res Date: 2019-12-05 Impact factor: 5.922
Authors: Sonia López; Alfonso Buil; Jordi Ordoñez; Juan Carlos Souto; Laura Almasy; Mark Lathrop; John Blangero; Francisco Blanco-Vaca; Jordi Fontcuberta; José Manuel Soria Journal: Eur J Hum Genet Date: 2008-06-18 Impact factor: 4.246
Authors: Dana C Crawford; Ze Peng; Jan-Fang Cheng; Dario Boffelli; Magdalena Ahearn; Dan Nguyen; Tristan Shaffer; Qian Yi; Robert J Livingston; Mark J Rieder; Deborah A Nickerson Journal: Hum Hered Date: 2008-07-09 Impact factor: 0.444
Authors: Erdembileg Anuurad; Jill Rubin; Alan Chiem; Russell P Tracy; Thomas A Pearson; Lars Berglund Journal: J Clin Endocrinol Metab Date: 2008-02-05 Impact factor: 5.958
Authors: Rahul C Deo; James G Wilson; Chao Xing; Kim Lawson; W H Linda Kao; David Reich; Arti Tandon; Ermeg Akylbekova; Nick Patterson; Thomas H Mosley; Eric Boerwinkle; Herman A Taylor Journal: PLoS One Date: 2011-01-24 Impact factor: 3.240